3 recruiting, 2 completed, 1 active not recruiting, 1 not yet recruiting. 4 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Completed 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow HER2 Negative Breast Cancer: new trials by email Literature Review of HER2 Negative Breast Cancer trials Research Report on HER2 Negative Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shared Decision Making for Patients With HER2-negative Metastatic Breast Cancer (SDM-01) Shared Decision Making (SDM) Support Program - Breast Cancer, HER2 Negative Breast Cancer | Not applicable | Not yet recruiting | Federico II University | 120 | 2026-06-01 | 2026-05-11 |
| Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg - HER2 Negative Breast Cancer | Phase 2 | Recruiting | Yale University | 140 | 2025-07-09 | 2026-05-26 |
| Reverse HER2-negative Immune Resistant Breast Cancer Retinoic Acid, anti-PD-1 antibody and chemotherapy - HER2 Negative Breast Cancer | Phase 2 | Recruiting | Fudan University | 10 | 2025-02-12 | 2025-11-17 |
| A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) GI-102 subcutaneous (SC), GI-102, doxorubicin - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | GI Innovation, Inc. | 358 | 2023-05-30 | 2024-11-25 |
| Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging Response monitoring (no intervention) - HER2 Negative Breast Cancer | Active not recruiting | New Mexico Cancer Research Alliance | 30 | 2018-04-16 | 2025-05-22 | |
| Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer Biomarker Analysis - Breast Cancer, HER2 Positive Breast Cancer | Completed | Cancer Trials Ireland | 330 | 2012-10-12 | 2025-07-08 | |
| Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer Eribulin, Cyclophosphamide, Docetaxel - HER2 Negative Breast Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 76 | 2012-06-01 | 2016-11-04 |
Breast Neoplasms (3) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Melanoma (1) · Neoplasm Metastasis (1) · Sarcoma (1)
Neoplasms (4) · Neoplasms by Site (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Breast Diseases (3) · Adenocarcinoma (1) · Carcinoma (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1)
eribulin (2) · Anastrozole (1) · Bevacizumab (1) · Chemotherapy, Adjuvant (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Drug Therapy (1) · Goserelin (1) · Letrozole (1) · Paclitaxel (1) · SDM (1) · Tretinoin (1) · pembrolizumab (1) · ribociclib (1)
Cancer Trials Ireland (1) · Federico II University (1) · Fudan University (1) · GI Innovation, Inc. (1) · New Mexico Cancer Research Alliance (1) · SCRI Development Innovations, LLC (1) · Yale University (1)
United States (4) · China (1) · Ireland (1) · South Korea (1)
Denise A Yardley, MD (1) · Jing Du (1) · Nari Yun, PhD (1) · Stefan Posse, PhD (1)